Keywords: اورودیلاتین; designer natriuretic peptide; drug development; heart failure; hypertension; natriuretic peptide; ANP; A-type natriuretic peptide; AS-BNP; alternatively spliced variant of BNP; BNP; B-type natriuretic peptide; BP; blood pressure; CD-NP; cenderitide; cGMP;